Photochemistry-based immune modulation in the treatment of cutaneous leishmaniasis

The destruction of infectious pathogens by photodynamic therapy (PDT) is an emerging modality. We demonstrated the efficacy of PDT for the management of cutaneous leishmaniasis in our previous studies. However, much remains to be done for the improvement of PDT regimens. The modulation of the immune response by photochemistry is an exciting but under-explored area of PDT research. The goal of this study is to understand the mechanisms of the augmentation of the host immune response after PDT of cutaneous leishmaniasis (CL). We found that PDT with phenoxiazine analogues was capable for induction of Th1 immune response due to stimulation of IL- 12 production by dendritic cells. Single PDT treatment facilitated fast healing of the CL lesions due to effective parasite eradication and augmentation of the immune system. Comparative study with different photosensitizers (PS) (porphyrins, pehnoxiazines) demonstrated different immunomodulating properties of PDT depending on chemical class of PS. Knowing the particular profiles and immunomodulating properties of the pertinent PSs allows us to select the optimal PS with regards to both the photodestructive and immunostimulating potential.

[1]  P. Desjeux.  Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.

[2]  N. Peters,et al.  Immune privilege in sites of chronic infection: Leishmania and regulatory T cells , 2006, Immunological reviews.

[3]  Y. Belkaid,et al.  Development of a Natural Model of Cutaneous Leishmaniasis: Powerful Effects of  Vector Saliva and Saliva Preexposure on the Long-Term Outcome of Leishmania major Infection in the Mouse Ear Dermis , 1998, The Journal of experimental medicine.

[4]  D. Sacks,et al.  Re‐examination of the immunosuppressive mechanisms mediating non‐cure of Leishmania infection in mice , 2004, Immunological reviews.

[5]  The leishmaniases. Report of a WHO Expert Committee. , 1984, World Health Organization technical report series.

[6]  D. Sacks,et al.  The immunology of susceptibility and resistance to Leishmania major in mice , 2002, Nature Reviews Immunology.

[7]  T. Ruzicka,et al.  [Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality]. , 2004, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[8]  Michael R Hamblin,et al.  Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model , 2008, Proceedings of the National Academy of Sciences.

[9]  S. Sakaguchi.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.

[10]  T. Hasan,et al.  Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation , 2007, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[11]  S. Sundar,et al.  Oral miltefosine for the treatment of Indian visceral leishmaniasis. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  J. Berman,et al.  Advances in leishmaniasis , 2005, The Lancet.

[13]  C. Jaffe,et al.  Treatment of cutaneous leishmaniasis with photodynamic therapy. , 2003, Archives of dermatology.

[14]  S. Flamant,et al.  Enhanced cloning efficiency of mouse bone marrow macrophage progenitors correlates with increased content of CSF-1 receptor of their progeny at low oxygen tension. , 2003, Microbes and infection.

[15]  R. Schaub,et al.  Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response , 1993, The Journal of experimental medicine.

[16]  al-Madani Aa.  Cutaneous leishmaniasis of the Old World. , 2003 .

[17]  P. Coleman,et al.  Anthroponotic Cutaneous Leishmaniasis, Kabul, Afghanistan , 2003, Emerging infectious diseases.

[18]  R. Reinhardt,et al.  Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. , 2008, International journal for parasitology.

[19]  M. Ouellette,et al.  Leishmaniasis: drugs in the clinic, resistance and new developments. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[20]  C. Jaffe,et al.  Treatment of cutaneous leishmaniasis with photodynamic therapy. , 2003, Archives of dermatology.

[21]  S. Brooker,et al.  Epidemiology of anthroponotic cutaneous leishmaniasis in Afghan refugee camps in northwest Pakistan. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[22]  S. Croft,et al.  Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. , 2007, International journal of antimicrobial agents.

[23]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[24]  T. Hasan,et al.  Parasiticidal effect of δ‐aminolevulinic acid‐based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells , 2007, Experimental dermatology.

[25]  Malcolm W R Reed,et al.  The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[26]  J. Norton,et al.  Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. , 1990, Journal of the National Cancer Institute.

[27]  B W Henderson,et al.  Role of cytokines in photodynamic therapy-induced local and systemic inflammation , 2003, British Journal of Cancer.

[28]  Barbara W Henderson,et al.  Generation of effective antitumor vaccines using photodynamic therapy. , 2002, Cancer research.

[29]  S. Brooker,et al.  Leishmaniasis in Refugee and Local Pakistani Populations , 2004, Emerging infectious diseases.

[30]  Shyam Sundar,et al.  Injectable paromomycin for Visceral leishmaniasis in India. , 2007, The New England journal of medicine.

[31]  J K Hoober,et al.  Photodynamic immunopotentiation: in vitro activation of macrophages by treatment of mouse peritoneal cells with haematoporphyrin derivative and light. , 1991, European journal of cancer.

[32]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.